^
    Back
    Association details:
    Biomarker:PTEN deletion
    Cancer:Prostate Cancer
    Drug:GSK2636771 (PI3Kβ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kß inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

    Published date:
    07/19/2021
    Excerpt:
    CONTRADICTING EVIDENCE: In this Phase I study (NCT02215096), patients with PTEN-deficient mCRPC...the 12-week non-PD rate was 50% (95% CI: 28.2-71.8%, n=22); 1 (3%) patient achieved a radiographic partial response lasting 36 weeks. 4/34 (12%) patients had prostate-specific antigen reduction of {greater than or equal to}50%.... GSK2636771 plus enzalutamide in patients with PTEN-deficient mCRPC after failing enzalutamide, limited antitumor activity was observed.
    Secondary therapy:
    enzalutamide
    DOI:
    10.1158/1078-0432.CCR-21-1115
    Trial ID:
    NCT02215096
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ESMO 2018
    Title:

    NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss

    Published date:
    10/01/2018
    Excerpt:
    Pts received GSK2636771 400mg/day (28-days cycles)….One pt (4.5%) with prostate ca (PTEN deletion, MPRSS2-ERG fusion) attained a partial response…
    DOI:
    https://doi.org/10.1093/annonc/mdy279.406
    Trial ID:
    NCI-MATCH